Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab combined with chemotherapy in advanced non-small cell lung cancer
ChiCTR2000033239Phase 4Not yet recruiting
- Sponsor
- Zhejiang Jinhua Guangfu Tumor Hospital
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Zhejiang Jinhua Guangfu Tumor Hospital. Primary endpoints: Treatment-emergent adverse events, Overall response rate and 4 more. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000033239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033239.